Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES D. CARNEGIE & CO IN CONNECTION WITH ITS LISTING ON NASDAQ STOCKHOLM’S MAIN MARKET
Mandate

VINGE ADVISES D. CARNEGIE & CO IN CONNECTION WITH ITS LISTING ON NASDAQ STOCKHOLM’S MAIN MARKET

May 08, 2015

D. Carnegie & Co (publ) has been approved for listing on Nasdaq Stockholm’s main market with the first day of trading on 12 May 2015.

D. Carnegie & Co is a property company focusing on residential properties in the Greater Stockholm region and other growth areas. The company’s business concept is to own property portfolios slated for a gradual renovation of apartments in conjunction with the natural turnover of tenants.

Vinge’s team primarily consisted of Jesper Schönbeck, Rikard Lindahl, Adam Sandberg and Nils‑Fredrik Dehlin.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026